TRAIL-R1 Is a Negative Regulator of Pro-Inflammatory Responses and Modulates Long-Term Sequelae Resulting from Chlamydia trachomatis Infections in Humans (vol 9, e93939, 2014) by Al-Kuhlani, M et al.
UC Irvine
UC Irvine Previously Published Works
Title
TRAIL-R1 Is a Negative Regulator of Pro-Inflammatory Responses and Modulates Long-Term 
Sequelae Resulting from Chlamydia trachomatis Infections in Humans (vol 9, e93939, 2014)
Permalink
https://escholarship.org/uc/item/79m7p6wx
Journal
PLOS ONE, 9(8)
ISSN
1932-6203
Authors
Al-Kuhlani, M
Rothschild, J
Pal, S
et al.
Publication Date
2014-08-22
DOI
10.1371/journal.pone.0106964
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
TRAIL-R1 Is a Negative Regulator of Pro-Inflammatory
Responses and Modulates Long-Term Sequelae Resulting
from Chlamydia trachomatis Infections in Humans
Mufadhal Al-Kuhlani1, James Rothchild5, Sukumar Pal2, Luis M. de la Maza2., Sander Ouburg3,
Servaas A. Morre´3,4., Deborah Dean5,6,7., David M. Ojcius1*.
1Department of Molecular Cell Biology, and Health Sciences Research Institute, University of California Merced, Merced, California, United States of America,
2Department of Pathology and Laboratory Medicine, University of California Irvine, Irvine, California, United States of America, 3 Laboratory of Immunogenetics, Medical
Microbiology and Infection Prevention, Research School V-ICI, VU University Medical Center, Amsterdam, The Netherlands, 4 Institute of Public Health Genomics,
Department of Genetics and Cell Biology, Research School GROW, University of Maastricht, Maastricht, The Netherlands, 5Center for Immunobiology and Vaccine
Development, Children’s Hospital Oakland Research Institute, Oakland, California, United States of America, 6Graduate Program in Bioengineering, University of California,
Berkeley and San Francisco, California, United States of America, 7Department of Medicine, University of California San Francisco, San Francisco, California, United States
of America
Abstract
The immune system eliminates Chlamydia trachomatis infection through inflammation. However, uncontrolled
inflammation can enhance pathology. In mice, TNF-related apoptosis-inducing ligand receptor (TRAIL-R), known for its
effects on apoptosis, also regulates inflammation. In humans, the four homologues of TRAIL-R had never been investigated
for effects on inflammation. Here, we examined whether TRAIL-R regulates inflammation during chlamydial infection. We
examined TRAIL-R1 single nucleotide polymorphisms (SNPs) in an Ecuadorian cohort with and without C. trachomatis
infections. There was a highly significant association for the TRAIL+626 homozygous mutant GG for infection vs no infection
in this population. To confirm the results observed in the human population, primary lung fibroblasts and bone marrow-
derived macrophages (BMDMs) were isolated from wildtype (WT) and TRAIL-R-deficient mice, and TRAIL-R1 levels in human
cervical epithelial cells were depleted by RNA interference. Infection of BMDMs and primary lung fibroblasts with C.
trachomatis strain L2, or the murine pathogen C. muridarum, led to higher levels of MIP2 mRNA expression or IL-1b secretion
from TRAIL-R-deficient cells than WT cells. Similarly, depletion of TRAIL-R1 expression in human epithelial cells resulted in a
higher level of IL-8 mRNA expression and protein secretion during C. trachomatis infection. We conclude that human TRAIL-
R1 SNPs and murine TRAIL-R modulate the innate immune response against chlamydial infection. This is the first evidence
that human TRAIL-R1 is a negative regulator of inflammation and plays a role in modulating Chlamydia pathogenesis.
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Introduction
Chlamydia trachomatis is the leading cause of bacterial sexually-
transmitted diseases (STDs) and the main cause of preventable
blindness worldwide _ENREF_1[1]. According to the Centers for
Disease Control, there were more than 1.3 million reported cases
in the United States in 2010, which corresponds to an increase of
,8% in comparison to 2008 [2]. The 19 known serovars of C.
trachomatis are categorized into three disease groups: ocular,
urogenital, and the invasive lymphogranuloma venereum (LGV).
The latter pathogens include the L1, L2, L2a, and L3 strains that
infect the reticuloendothelial system involving predominantly the
lymph nodes [3,4].
Infection of epithelial cells by chlamydiae initiates an inflam-
matory response through ligation of Toll-like receptors (TLRs) and
Nod-like receptors [5,6]. These receptors are usually expressed by
immune cells such as macrophages, dendritic cells and neutrophils,
but also mucosal epithelial cells [7–10]. The engagement of TLRs
by microbial products of chlamydiae, such as lipopolysaccharide,
initiates the TLR signaling cascade [5,6]. Once activated, the
Toll/IL-1R (TIR) domain of TLR interacts with various adaptors,
such as MyD88, which in turn recruits and activates additional
adaptor proteins, including the IL-1 receptor-associated kinases
(IRAK) and (TNF)-receptor-associated factor 6 (TRAF6) [11-13].
TRAF6 then activates various proteins that ultimately lead to the
phosphorylation of inhibitor of kappa B alpha (I-kBa), which
subsequently undergoes degradation via ubiquitination. The
degradation of I-kB releases the activated nuclear factor-kB (NF-
kB), which allows it to translocate into the nucleus and stimulate
the expression of pro-inflammatory components, such as interleu-
kin (IL)-8, IL-6, IL-18, IL-1a and granulocyte-macrophage
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colony-stimulating factor (GM-CSF) that recruit and activate
various immune cells [14–17].
Clearance of infection through inflammation is often an efficient
process. However, the mechanisms for clearing chlamydial
infection varies among individuals whose immune systems, in
addition to clearing the infection, can cause chronic inflammation
[18,19]. Chronic inflammation and tissue damage seen during C.
trachomatis infections is caused not by the infectious organism, but
by the host’s immune response to these pathogens. Therefore
inflammation needs to be tightly regulated to avoid uncontrolled
immune responses.
Negative regulation of inflammation is accomplished at multiple
levels throughout the TLR signaling pathways [20,21]. The first
level of regulation involves a decrease in the expression of TLR as
the presence of soluble TLRs that can compete with the agonist
[22]. Soluble forms of TLR2 and TLR4 dampen the host immune
response against infection by preventing the activation of TLR-
mediated signaling [23,24]. Other regulators exert their effect
within the cytosol, downstream from TLR ligation. The cytosolic
regulators target different components of the TLR signaling
pathway such as MyD88, IRAK1, TRAF6, and phosphoinositide
3-kinase [25–30].
The transmembrane receptor of TNF-related apoptosis-induc-
ing ligand receptor (TRAIL-R) is a member of the tumor necrosis
factor receptor superfamily that lacks a TIR domain [31]. In
addition to its well-established role in inducing apoptosis, TRAIL-
R has been reported to modulate inflammation of the host cells in
response to various pathogens and diseases [32–34]. Four different
TRAIL-Rs have been identified in humans (the transmembrane
proteins, TRAIL-R1 through -R4, and a soluble osteoprotegrin)
and one full-length receptor in mice [35,36] (Figure 1). TRAIL-R1
and TRAIL-R2, also known as Death Receptor (DR)-4 and DR-5,
are the only known receptors that are capable of selectively killing
transformed cells but not normal cells, while TRAIL-R3 and
TRAIL-R4 serve as decoys [37,38]. TRAIL-R-deficient mice
develop normal populations of immune cells [33,39,40], but
challenge of these mice with different pathogens and stimuli for
TLR2, TLR3 and TLR4 results in enhanced ability of the innate
immune system to clear the infection and increased production of
different pro-inflammatory-cytokines such as IFN-b, compared to
wildtype mice [33]. The ability of TRAIL-R to downregulate TLR
signaling seems to be through decrease activation of NF-kB by
stabilizing the I-kBa subunit [33].
While murine TRAIL-R is established as a negative regulator of
inflammation, and some progress has been made in understanding
the role of TRAIL-R1 in the immune response in humans,
nothing is known about the potential role of TRAIL-R1 as a
negative regulator of inflammation in humans.
Clear differences in the clinical course of C. trachomatis infections
in women have been observed, which are not explained by
bacterial factors. This suggests that there might be differences in
the host genetic background associated with the recognition of
pathogens and the immune response that ensues. Indeed, recent
research indicates the relevance for studying the host genetic
background in relation to disease susceptibility. In one study, an
analysis of the lymphoproliferative responses to C. trachomatis
antigen among Gambian monozygotic versus dizygotic twins in a
trachoma endemic region indicated an almost 40% contribution of
heritability to the observed differences in the response [41].
The effect of single nucleotide polymorphisms (SNPs) on the
function of TRAIL-R1 have not been studied yet in C. trachomatis
infections. Four TRAIL-R1 SNPs have an effect on the expression
of the protein demonstrated as upregulation in silico in human
populations based on data in HapMap (http://www.hapmap.org/),
but their ability to enhance or diminish inflammation among
populations at risk for C. trachomatis infection has never been
examined.
In this study, we investigate the effect of TRAIL-R1 SNPs in
regulating susceptibility to C. trachomatis infection among women
from a population at risk for STDs, identify TRAIL-R1 as a
downregulator of inflammation in human cells, and elucidate the
role of murine TRAIL-R in the inflammatory response against
chlamydial infection in vitro.
Results and Discussion
Association of the TRAIL-R1 SNPs with C. trachomatis
infection in a human population
A well-defined Ecuadorian cohort with and without C.
trachomatis infections was tested for the four known TRAIL-
R1 through -R4 SNPs that could be associated with pathology due
to infection.
The human population consisted of 760 women who enrolled in
the study. Their ages ranged from 18 to 55 years; the mean age
was 29 years. Nine women were excluded from the analyses due to
insufficient data. The prevalence of C. trachomatis was 16.7% (126
women); there were no patients with human immunodeficiency
virus (HIV-1) infection, and 3.2% (4 women) were coinfected with
Neisseria gonorrhoeae. Table 1 shows the risk factors for C. trachomatis
infection. As expected, women younger than 24 years were at
increased risk for C. trachomatis infection (p,0.0003; OR 2.3807;
CI 1.4935 to 3.7950), as were women with onset of sexual activity
during adolescence. There were no significant differences for
infection associated with number of sex partners or prior history of
STDs. In addition, the diversity of ompA genotypes for the 126
women included Ba (6 women), D (19), E (29), F (25), I (5), J (13),
Ja (10), L2 (9), L2b (7), and L3 (3). There were no differences
among risk groups for infecting genotype.
The distribution of TRAIL-R1 haplotypes differed between
women with and without C. trachomatis infection (Table 2). The
TRAIL-R1+626 homozygous mutant GG was found to be
significantly associated with C. trachomatis infection versus no
infection (p,0.0001; OR: 5.3, CI: 2.3763 to 11.8553). There were
no synergistic effects for any combination of SNPs. There was no
association of any ompA genotype with this SNP.
We have previously shown the association of host genetic factors
(genes encoding TLR-2, TLR-4 and TLR-9) with the susceptibility
and course of C. trachomatis infection [42–44]. Recently, two other
studies [45,46] showed a role for TLR SNPs in the prevalence of
pelvic inflammatory disease (PID) among African American
women. As TRAIL-R1 can downregulate TLR signaling through
decreased activation of NF-kB, our current findings underline the
importance of TRAIL-R1 and TLR signaling in the defence
against C. trachomatis infection. This is consistent with the
upregulation of the TRAIL-R1 SNPs in silico.
MIP-2 expression and IL-1b secretion in TRAIL-R-deficient
lung fibroblasts
Most previous studies have focused on the ability of TRAIL-R
to induce apoptosis, although some studies also report on the effect
of TRAIL-R on infection in animal models [47]. A role for
TRAIL-R as a downregulator of TLR-mediated signaling has
been reported only for the murine TRAIL-R [33]. In this study,
the potential role of TRAIL-R in regulating inflammation during
chlamydial infection was examined by isolating primary lung
fibroblasts from WT and TRAIL-R-deficient mice and infecting
them with C. muridarum (MoPn) and C. trachomatis
(LGV/L2). MoPn is an appropriate strain for infecting lung
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fibroblasts since it causes pneumonitis in mice. As it has not been
possible until now to culture primary cervical epithelial cells from
mice, lung fibroblasts were also used to characterize the cellular
response to the LGV strain of C. trachomatis (L2), which is known to
induce a stronger response in the infected cells [48],[49,50]. Since
C. muridarum is closely related to the C. trachomatis human
strains, it has been widely used to study the pathogenesis of
chlamydial disease in the reproductive and respiratory tracts of the
mouse model [49,50]. As shown in Figure 2A, TRAIL-R-deficient
fibroblasts express macrophage inflammatory protein-2 (MIP-2, a
murine homologue of human IL-8) at higher levels in response to
both C. muridarum and C. trachomatis infection than WT fibroblasts.
However, the secretion of the cytokine IL-1b in response to C.
muridarum infection was minimal with no significant difference
between the WT and TRAIL-R-deficient fibroblasts (Figure 2B).
On the other hand, infection of the fibroblasts with the L2 strain of
C. trachomatis induced the secretion of IL-1b more than 60-fold,
compared with uninfected cells (Figure 2A). Similarly to the
increased MIP-2 expression during C. trachomatis infection,
TRAIL-R-deficient fibroblasts infected with C. trachomatis secrete
higher levels of IL-1b than the WT cells (Figure 2B).
Even though MIP-2 expression but not IL-1b secretion is
stimulated in response to C. muridarum infection, C. trachomatis
infection led to production of both pro-inflammatory mediators,
and their levels were enhanced in the absence of TRAIL-R.
Expression of pro-inflammatory mediators in TRAIL-R-
deficient macrophages
Epithelial cells are the preferred host cells for most chlamydial
species, but macrophages can also be infected, or at least
Figure 1. Multiple sequence alignment of human and murine TRAIL-Rs. Sequence alignment shows all four human TRAIL-Rs (hTRAIL-R) and
murine TRAIL-R (mTRAIL-R). FASTA files were obtained from the Uniport database at (http://www.uniprot.org). Amino acid (AA) sequences of hTRAIL-
R2-4 and mTRAIL-R were aligned in comparison to hTRAIL-R1 using the ClustalW algorithm. The percentage of homology, insertion or loss of AA
sequences, and the unique features of the different receptors are presented with different patterns as indicated.
doi:10.1371/journal.pone.0093939.g001
Table 1. Risk of C. trachomatis infection in humans by age group*.
Risk 18–23 yrs (n =251) P value 24–29 yrs (n=250) P value .29 yrs (n =250) P value
CT+ CT- CT+ CT- CT+ CT-
Age** 65 186 32 218 27 223 p,0.0003
Onset sexual activity:
adolescence 65 112 P = 0.0018 32 150 p,0.018 27 177 p,0.0633
adulthood 0 74 0 68 0 46
No. of sex partners:
1 27 99 NA 10 75 NA 10 70 NA
.1 38 87 22 143 17 153
Prior history STDs:
Yes 40 100 NA 19 111 NA 17 103 NA
No 25 86 13 107 10 120
Co-STD infections:
HIV 0 251 NA 0 250 NA 0 250 NA
GC 2 249 NA 1 249 NA 1 249 NA
*Nine women were excluded due to missing data.
**Calculated across all age groups.
doi:10.1371/journal.pone.0093939.t001
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Table 2. Distribution of four TRAILR1 SNPs in C. trachomatis positive (CT+) and negative (CT-) women in Ecuador.
CT+ CT- P value
Wildtype Heterozygote Mutant Wildtype Heterozygote Mutant
TRAILR1 +626 C.G 13.2% 40.4% 46.4% 35.9% 39.9% 24.2% p,0.0001
TRAILR1 +683 A.C 59.2% 27.1% 13.7% 64.2% 27.9% 7.9% NS
TRAILR1 +422 G.A 22.7% 51.9% 25.4% 25.3% 50.9% 23.8% NS
TRAILR1 +1387 A.G 83.0% 20.8% 6.2% 79.1% 15.9% 5.0% NS
doi:10.1371/journal.pone.0093939.t002
Figure 2. TRAIL-R deficiency increases MIP-2 and IL-1b levels in primary lung fibroblasts in response to a Chlamydia infection.WT and
TRAIL-R-deficient cells were infected with either C. muridarum (MoPn) or C. trachomatis (L2) strains at an MOI of 1 for 24 hrs. (A) mRNA levels of MIP-2
was measured via qPCR. Cycle threshold (Ct) values were normalized to GAPDH and relative expression (DDCt) was calculated compared to
uninfected cells. (B) ELISA measurement for IL-1b. The ratio of increased IL-1b level was calculated with respect to uninfected cells. Error bars
represent standard deviations from 3 separate experiments. * indicates p,0.05; ** indicates p,0.01, compared to infected WT cells.
doi:10.1371/journal.pone.0093939.g002
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stimulated, with Chlamydia [51–53]. We thus isolated bone marrow
cells from WT and TRAIL-R-deficient mice and induced their
differentiation into bone-marrow derived macrophages (BMDMs).
Flow cytometry analysis, shown in Figure S1, confirmed that the
great majority of cultured cells expressed the specific markers,
CD11b and F4/80. Compared with the uninfected groups,
BMDMs infected with C. muridarum expressed low levels of MIP-2
and secreted little IL-1b, with no significant difference between
WT and TRAIL-R-deficient cells (Figure 3A, B). In contrast,
BMDMs infected with C. trachomatis L2 expressed high levels of
both MIP-2 and IL-1b, which were enhanced by TRAIL-R
deficiency (Figure 3A, B).
Expression of TRAIL-R1 through TRAIL-R4 in human cells
With few exceptions, studies of the role of TRAIL-R in
regulating inflammation had been performed using the mouse
model [33]. We therefore first examined via PCR whether the four
human TRAIL-Rs (TRAIL-R1 through TRAIL-R4) are ex-
pressed in cells that are commonly used in research on innate
immunity and chlamydial infections: the cervical epithelial cell
line, HeLa; the human monocyte cell line, THP-1; and the human
embryonic kidney cell line, HEK-293. As shown in Figure 4A,
both HeLa and HEK293 cells express high levels of all four
subtypes of TRAIL-R, with the exception to TRAIL-R3, which is
Figure 3. TRAIL-R-deficient BMDMs express higher MIP-2 and IL-1b levels in L2- but not MoPn-infected cells. BMDMs were infected
with C. muridarum (MoPn) or C. trachomatis (L2) as for fibroblasts in Figure 2 above. qPCR analysis was performed for MIP-2 (A), and IL-1b secretion
was measured by ELISA (B). Error bars represent standard deviations from 3 separate experiments. * indicates p,0.05; ** indicates p,0.01, compared
to infected WT cells.
doi:10.1371/journal.pone.0093939.g003
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barely expressed in HeLa cells; while the THP-1 cell line expressed
only TRAIL-R2 and TRAIL-R4.
Expression and secretion of IL-8 in TRAIL-R1-deficient
cervical epithelial cells
The protein structures of both TRAIL-R1 and TRAIL-R2
resemble each other (Figure 1) [54] [55]. We thus chose to focus
our initial studies on TRAIL-R1 given its homology to murine
TRAIL-R. To evaluate the role of TRAIL-R1 in vitro, specific
shRNA lentiviral particles were used to deplete TRAIL-R1 in
HeLa cells. As measured by qPCR, there was a significant
reduction of TRIAL-R1 mRNA levels in transduced HeLa cells,
compared to the WT and non-target shRNA control cells (sh Ctrl)
(Figure 4B).
Secretion of the chemokine IL-8, which is an indicator of early
stages of the inflammatory response, has been previously described
for HeLa cells infected with Chlamydia [14,17,56]. The levels of IL-
8 mRNA expression or IL-8 protein secretion in response to C.
trachomatis infection in TRAIL-R1-depleted cells were significantly
higher than in infected WT or non-target shRNA control cells
(Figure 5A, B).
Concluding remarks
We here show that TRAIL-R can negatively regulate initiation
of inflammation in humans and mice during chlamydial infection.
The role of TRAIL-R as a negative regulator of inflammation
had been previously addressed in the murine model [33]. The ex-
vivo results presented here demonstrate that TRAIL-R is involved
in regulation of pro-inflammatory cytokine production in primary
lung fibroblasts in response to C. trachomatis or C. muridarum
infection. However, infection with C. trachomatis, but not C.
muridarum, is capable of inducing such responses in the BMDMs.
The different responses to C. muridarum infection observed between
lung fibroblasts and BMDMs, and between C. trachomatis and C.
muridarum infection of BMDMs, suggest that the mechanisms of
negative regulation of inflammation by TRAIL-R may depend on
the tissues being infected or the specific pathogen strain. In fact,
the L2 strain of C. trachomatis used in these studies is a pathogen of
the reticuloendothelial system involving predominantly the lymph
nodes, whereas C. muridarum is not.
This is the first report that human TRAIL-R1 also functions as
a negative regulator of inflammation. The exact mechanisms used
by TRAIL-R1 to dampen pro-inflammatory responses in humans
remains to be investigated, but could provide potential biomarkers
indicative for the course of infection. The link between TLR
Figure 4. Expression of TRAIL-R1-R4 and depletion of TRAIL-R1 in human cells. (A) A 2% agarose gel electrophoresis gel shows RT-PCR
amplification of TRAIL-R1 (214 bp), TRAIL-R2 (145 bp), TRAIL-R3 (141 bp) and TRAIL-R4 (271 bp) mRNA from HeLa, THP-1 and HEK293 cell lines. (B)
HeLa cells transduced with TRAIL-R1 specific shRNA (sh-TRAIL-R1) show a reduced level of TRAIL-R1 mRNA when measured by real-time PCR and
compared with wildtype (WT) and non-target control (sh Ctrl). Error bars represent standard deviations from at least 3 independent experiments. ***
indicates p,0.001 (p= 0.0152) and ‘‘n.s’’ indicates ‘‘not significant’’ (p=0.1229) compared with WT. The p value for sh-TRAIL-R1 compared to non-
target control is 0.0107
doi:10.1371/journal.pone.0093939.g004
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signaling and apoptosis has been reported in various studies where
proteins that are known to facilitate apoptosis, such as Nur77,
PKR or TRAIL, are up-regulated due to activation of some TLR
pathways [57-62]. Since TRAIL-R1 is a trigger of apoptosis via
the adaptor domain, Fas-associated death domain (FADD) and
caspase-8, and C. trachomatis modulates host cell death during
infection, evaluating the effect of TRAILR-R1 on the activation of
the apoptotic pathway during chlamydial infection may contribute
to explaining the mechanism of action of TRAIL-R1 as a negative
regulator. Indeed, the pattern of low mRNA expression of
TRAIL-R1 at early times of infection and the increase at later
stages (data not shown) could be related to the time-course of C.
trachomatis infection on apoptosis of the infected cells [34,63].
Another indicator for the possible involvement of FADD in the
function of TRAIL-R as a negative regulator is the observation
that FADD can modulate the activity of NF-kB and IL-1b with a
pattern that is similar to TRAIL-R [64-66]. In addition, the role
that the truncated receptors, TRAIL-R3 and TRAIL-R4, may
play during inflammation has never been addressed. It is tempting
to speculate that, behaving as dominant negative versions of
TRAIL-R1, the truncated receptors may have the opposite effect
of TRAIL-R1, enhancing rather than dampening inflammation. It
is possible that the absence of TRAIL-R results in a decrease of
apoptosis in the inflamed tissue and, therefore, increase the
intensity of the inflammatory response. Characterization of this
gene family may help to gain a better understanding of their role
in Chlamydia pathogenesis and could lead to the development of
therapeutic approaches to minimize the side effects of inflamma-
tion when infection occurs.
Methods and Materials
Human study populations
Female commercial sex workers (n = 760) ranging in age from
18-55 years were recruited and enrolled in the study through
health care clinics in Quito, Ecuador, from August 2002 to August
2005. Potential participants were excluded if they had taken
antibiotics within the four weeks preceding study enrollment, had
a history of any cancer diagnosis or collagen vascular disease, or
were unwilling to complete the study questionnaire and provide
biological samples. Written informed consent was obtained from
all participants, and approval for the study was granted by the
Institutional Review Boards (IRBs) of Children’s Hospital Oakland
Research Institute and La Pontificia Universidad Cato´lica del
Ecuador, Quito, Ecuador, according to the tenets of the
Declaration of Helsinki.
All study participants were administered survey questionnaires
about risk factors for HIV and other sexually transmitted
infections. Participants were excluded from the final analyses if
either their C. trachomatis diagnostic status or SNP data were
missing.
C. trachomatis detection and ompA genotyping in
patient populations
Cervical swab samples were collected from the study partici-
pants using standard techniques and the presence of C. trachomatis
was determined and commercial nucleic acid amplification tests
(NAAT) (Amplicor; Roche Molecular Systems) [67]. Indetermi-
nate samples were resolved using an in-house PCR as previously
described [67].
All samples from the Ecuadorian population that were positive
by Amplicor and/or in-house PCR were subjected to ompA
genotyping as described elsewhere [68].
Haplotype determination
In order to determine the homogeneity or heterogeneity of the
Ecuadorian population, the four SNPs for TRAIL-R1 were
analyzed. The haplotypes were inferred using PHASE v2.1.1 [69]
and SNPHAP [70].
SNP detection
Genomic DNA was extracted from cryopreserved blood
samples using either the DNeasy Blood & Tissue Kit (Qiagen,
Valencia, CA) or the MagNaPure LC isolator (Roche Molecular
Biochemicals, Germany) according to the manufacturer’s instruc-
tions. Both techniques provided enough DNA for reproducible
genetic analyses. For the Ecuador population, single nucleotide
polymorphisms (SNPs) in amplified DNA fragments were identi-
fied by the Sequenom MassARRAY system that uses MALDI-
TOF Mass Spectrometry. The assays were run at the W.M. Keck
Foundation Biotechnology Resource Laboratory at Yale Univer-
sity, New Haven, Connecticut. Custom software was used to
design SNP assays and analyze the data. Different size primer
Figure 5. Increased IL-8 expression and secretion in TRAIL-R1-
depleted cervical epithelial cells. HeLa cells were infected with C.
trachomatis strain (L2) at an MOI of 1. (A) RNA was isolated 24 hpi for
quantification of IL-8 expression using qPCR. The data were normalized
to GAPDH, and infected wild type HeLa cells were used to calculate the
relative expression (DDCt). Error bars represent standard deviations
from 4 separate experiments. ** indicates p= 0.0075; and ‘‘n.s.’’
indicates ‘‘not significant’’ (p=0.1736), compared with infected WT
cells. The p value for sh-TRAIL-R1 compared with non-target control is
0.01. (B) ELISA measurement of IL-8 secretion. Error bars represent
standard deviations from 4 separate experiments. * indicates p,0.05;
(p=0.0394); and ‘‘n.s.’’ indicates ‘‘not significant’’ (p= 0.9332), compared
with infected WT cells. The p value for sh-TRAIL-R1 compared to non-
target control is 0.0479.
doi:10.1371/journal.pone.0093939.g005
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extension products were generated for the two alleles of a given
SNP. The presence of one or both alleles is scored by the software
for each sample. The assays were designed to interrogate four
SNPS per sample. These included TRAIL-R1 SNPs +422 G.A
(141 HisRArg; rs6557634); +626 C.G (209 Arg.Thr; rs20575);
+683 A.C (228 Glu.Ala; rs20576); and +1387 A.G (441
Lys.Arg; rs2230229).
Statistical analyses
Statistical analyses for the human data were performed as
previously described [71]. Briefly, the chi-square test was used for
determining frequency of SNP comparisons, the combined effect
of the SNPs and risk factors between the groups. Each SNP was
tested for Hardy-Weinberg equilibrium. Multivariate logistic
regression was used for analysis of STD risk factors, SNPs and
SNP interactions. Logic regression was also performed to identify
interactions among the SNPs as previously described [71]. Fisher’s
exact or x2 tests were also used to compare the SNP genotypes
between C. trachomatis positive and negative STD patients. STATA
10 was used for analyses (Texas). p values,0.05 were considered
statistically significant.
The statistical significance for the ex vivo and in vitro
experiments was evaluated using GraphPad Instat software
(GraphPad Software Inc, La Jolla, CA) by unpaired Student’s t-
test. A value of p,0.05 was considered significant. Data are
presented as the cumulative result of at least 3 independent
experiments, unless stated otherwise.
Chlamydia stocks
The L2 serovar (434 strain) of C. trachomatis and C. muridarum
(previously called C. trachomatis mouse pneumonitis (MoPn), strain
Nigg II) were grown in HeLa cells as described before [72,73].
The multiplicity of infection (MOI) for C. trachomatis and C.
muridarum was determined by infecting HeLa cell monolayer
cultures as previously described [73].
Eukaryotic cells
The human cervical carcinoma cell line, HeLa 229, was
obtained from American Type Culture Collection (ATCC). The
THP1 monocyte cell lines was previously described [74].
To isolate murine cells, TRAIL-R-deficient mice in the C57Bl/
6 background were obtained from Dr. Astar Winoto (University of
California, Berkeley) [33] and were housed at the University of
California, Irvine, Vivarium. The University of California, Irvine,
Animal Care and Use Committee approved all animal protocols.
The mice were euthanized with an overdose of xylazine plus
ketamine. To produce BMDMs, femurs from two WT and
TRAIL-R-deficient mice were cleaned from tissues and briefly
sterilized in 70% ethanol. BMDMs were prepared as described
elsewhere [33]. BMDM cells were harvested using trypsin and the
cell populations were analyzed by flow cytometry for the
expression of BMDM specific receptor using anti-mouse CD11b-
PE and F4/80-APC (eBiosciences). Flow cytometry data analysis
was performed using FlowJo software, version 7.6.1 (TreeStar).
Primary lung fibroblasts were prepared from wildtype and
TRAIL-R-deficient mice, following the procedures previously
described [75,76]. Fourteen days post isolation, the primary lung
fibroblasts were seeded into 12 well plates for infection assays, as
we previously described [77].
Generation of TRAIL-R1-depleted HeLa cells using
lentiviral shRNA
HeLa cells were seeded in 96-well plates and then transduced in
the presence of 8 mg/ml Polybrene for 48 hrs with shRNA-
TRAIL-R1 specific lentiviral particles purchased from Sigma-
Aldrich (catalog number NM?003842) at a multiplicity of infection
(MOI) of 1. Non-target shRNA control cells were also generated
using an irrelevant sequence (Sigma, SHC002 V). Cells success-
fully transduced with lentiviral particles were selected by the
addition of media containing 2.5 mg/ml puromycin (Sigma-
Aldrich). The knockdown efficiency of TRAIL-R1 was verified
by q-PCR analysis.
Ex vivo and in vitro cell culture and infection
Sixteen to twenty four hours prior to infection, 16106/well of
murine BMDMs, 16106 murine lung fibroblasts/well, or 56104
cells/well of HeLa cells were plated on 24 well plates in antibiotic
free culture media. Cells growing to about 60% confluency were
infected with either C. trachomatis (LGV/L2) or C. mur-
idarum (MoPn) as indicated at an MOI of 1.0 and incubated at
37uC with 5% CO2. Twenty four hours post infection (hpi),
supernatants were collected for ELISA analysis and infected cells
were lysed in RLT buffer for RNA isolation.
Reverse transcription and PCR (RT-PCR)
Total RNA were isolated from cells using the Qiagen RNeasy
kit (Qiagen) following the manufacturer’s instructions. The
synthesis of the complementary DNA (cDNA) templates were
conducted according to the manufacturer’s instructions (TaqMan,
Roch). The PCR was performed using Qiagen Fast Cycling PCR
Kit. PCR conditions included denaturation steps at 95uC for
5 min, followed by 35 cycles at 96uC for 5 sec, 60uC for 5 sec and
68uC for 5 sec followed by 72uC for 1 min. The PCR products
were separated by 2% agarose gel electrophoresis and visualized
using ethidium bromide. The primers are listed in Table S1.
Quantitative-PCR (qPCR)
Total RNA and cDNA were generated as explained above. The
q-PCR analysis was conducted in triplicates of 20 ml final volume
using Mx3000P (Stratagene, La Jolla, CA) with Brilliant III Ultra
Fast STBR Green qPCR master mix (Stratagene). Negative
controls include a no-RT control and no cDNA template control
(H2O alone). Real-time PCR included initial denaturation at 95uC
for 3 min, followed by 40 cycles at 95uC for 5 sec, 60uC for 20 sec,
and one cycle at 95uC for 1 min, 55uC for 30 sec, and 95uC for
30 sec. The averages of the collected data were normalized to the
activity of a house-keeping gene, GAPDH. For mouse BMDM
and lung fibroblasts, the relative expressions (DDCt) were
calculated using uninfected cells (WT or TRAIL-R deficient) as
a baseline. For the human cell line, infected wildtype HeLa cells
were used as a baseline for the DDCt calculation.
ELISA for cytokine secretion
The mouse IL-1b ELISA kit (eBioscience Cat# 88-7013-76)
and human CXCL8/IL-8 cytokine ELISA kit (R&D Systems,
DY208) were used according to manufacturer’s instructions.
Ratios of the secreted IL-1b and IL-8 were calculated in
comparison to the untreated samples.
Supporting Information
Figure S1 Representative flow cytometry dot plot of differenti-
ated BMDM cells. Cultured bone marrow cells were stained with
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BMDM-specific antibodies against mouse CD11b-PE and F4/80-
APC, seven days post-isolation.
(TIFF)
Table S1 List of primers used for qPCR.
(TIFF)
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